SlideShare ist ein Scribd-Unternehmen logo
1 von 108
ANTIPARKINSONIAN AGENTS MA. LENY ALDA G. JUSAYAN, MD DEPARTMENT OF PHARMACOLOGY
NEURODEGENERATIVE DISORDERS
HOW DOES THE BODY MOVES?
THE BRAIN CONTROLS MOVEMENT
 
 
 
 
CASE 1 ,[object Object]
PARKINSONISM ,[object Object],[object Object],[object Object],[object Object],[object Object]
The  UK Parkinson's Disease Society   Brain Bank  Criteria For Clinical Diagnosis: ,[object Object],[object Object],[object Object]
Motor Symptoms: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Nonmotor Symptoms: ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
What causes Parkinson’s Disease? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PATHOGENESIS: ,[object Object],[object Object],[object Object],[object Object],[object Object]
MOTOR SYMPTOMS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CHOREA ,[object Object],[object Object],[object Object]
TICS ,[object Object],[object Object],[object Object],[object Object]
ATHETOSIS ,[object Object],[object Object]
 
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
 
 
 
 
WHAT CAN BE DONE TO HELP PARKINSON’S SUFFERERS?
GOALS OF TREATMENT: ,[object Object],[object Object]
PATHOPHYSIOLOGIC  BASIS OF TREATMENT: ,[object Object]
CASE 2 ,[object Object],[object Object],[object Object]
REMEDIES FOR STEP 1: DOPAMINE REPLACEMENT
LEVODOPA ,[object Object],[object Object],[object Object],[object Object],[object Object]
PHARMACOKINETICS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINICAL USE: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ADVERSE EFFECTS: ,[object Object],[object Object]
ADVERSE EFFECTS: ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
DRUG INTERACTIONS: ,[object Object],[object Object],[object Object],[object Object]
CONTRAINDICATIONS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CASE 3 ,[object Object],[object Object]
PERIPHERAL DOPAMINE DECARBOXYLASE INHIBITORS (PDI) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
CASE 4 ,[object Object],[object Object]
DOPAMINE AGONISTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
ERGOT ALKALOIDS: ,[object Object],[object Object],[object Object],[object Object],[object Object]
ERGOT ALKALOID: ,[object Object],[object Object],[object Object],[object Object]
CLINICAL USE: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
NON-ERGOT DOPAMINE AGONISTS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
NON-ERGOT ALKALOIDS: ,[object Object],[object Object],[object Object]
ADVERSE EFFECTS: ,[object Object],[object Object],[object Object],[object Object],[object Object]
CONTRAINDICATIONS: ,[object Object],[object Object],[object Object],[object Object]
APOMORPHINE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
MONOAMINE OXIDASE INHIBITORS ,[object Object],[object Object]
SELEGILINE ( Deprenyl) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SELEGELINE ,[object Object],[object Object],[object Object],[object Object],[object Object]
DRUG INTERACTION: ,[object Object]
RASAGILINE ,[object Object],[object Object],[object Object]
CATHECO-O-METHYLTRANSFERASE INHIBITORS: ,[object Object],[object Object],[object Object]
CATHECOL-O-METHYLTRANSFERASE INHIBITORS: ( SELECTIVE) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
STALEVO ,[object Object],[object Object],[object Object]
 
SIDE EFFECTS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
AMANTADINE ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
CLINICAL USE: ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
CONTRAINDICATIONS: ,[object Object],[object Object]
ACETYLCHOLINE BLOCKING AGENTS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ADVERSE EFFECTS: ,[object Object],[object Object],[object Object],[object Object]
CONTRAINDICATIONS: ,[object Object],[object Object],[object Object]
[object Object]
 
SURGICAL PROCEDURES: ,[object Object],[object Object]
NEURONAL DEATH ,[object Object],[object Object],[object Object],[object Object]
NEURONAL DEATH ,[object Object],[object Object]
NEURONAL DEATH ,[object Object],[object Object]
ISCHAEMIC BRAIN DAMAGE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINICAL SCENARIO ,[object Object]
ALZHEIMER’S DISEASE ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
MOLECULAR MODEL FOR THE DEVELOPMENT OF ALZHEIMERS DISEASE
PATHOPHYSIOLOGY: ,[object Object],[object Object],[object Object],[object Object],[object Object]
PATHOPHYSIOLOGY: ,[object Object],[object Object]
AMYLOID PLAQUES ,[object Object]
NEUROFIBRILLARY TANGLES: ,[object Object],[object Object]
 
DRUGS FOR ALZHEIMER’S DISEASE
CHOLINESTERASE INHIBITOR:
CHOLINESTERASE INHIBITORS: ,[object Object],[object Object],[object Object],[object Object],[object Object]
TACRINE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
DONAZEPIL, RIVASTIGMINE, GALANTAMINE ,[object Object],[object Object]
ADVERSE EFFECTS: ,[object Object],[object Object],[object Object]
NEURONAL NICOTINIC RECEPTORS  (NNRs)
TARGACEPT ,[object Object],[object Object],[object Object]
[object Object],[object Object]
 
NMDA GLUTAMATE RECEPTOR INHIBITORS
MEMANTINE (Ebixa) ,[object Object],[object Object],[object Object],[object Object]
TREATMENT: ,[object Object],[object Object],[object Object],[object Object],[object Object]
THANK YOU !!!
POST –TEST: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Parkinsons disease
Parkinsons diseaseParkinsons disease
Parkinsons diseasemmurralii
 
Parkinson's disease pharmacology
Parkinson's disease pharmacologyParkinson's disease pharmacology
Parkinson's disease pharmacologyZuaib Aktar
 
Anti-Parkinson Drugs
Anti-Parkinson DrugsAnti-Parkinson Drugs
Anti-Parkinson Drugsvansh raina
 
Parkinson diseases
Parkinson diseasesParkinson diseases
Parkinson diseasesN K
 
Anti parkinsonian drugs
Anti parkinsonian drugsAnti parkinsonian drugs
Anti parkinsonian drugsSharique Ayaz
 
Antiepileptic drugs : Dr Rahul Kunkulol's Power point preparations
Antiepileptic drugs : Dr Rahul Kunkulol's Power point preparationsAntiepileptic drugs : Dr Rahul Kunkulol's Power point preparations
Antiepileptic drugs : Dr Rahul Kunkulol's Power point preparationsRahul Kunkulol
 
Drug induced parkinsonism
Drug induced parkinsonismDrug induced parkinsonism
Drug induced parkinsonismSai Siddharth M
 
Pathophysiology of Parkinsonism
Pathophysiology of ParkinsonismPathophysiology of Parkinsonism
Pathophysiology of ParkinsonismTural Abdullayev
 
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.Rajeshwari Netha
 
Parkinsonism, Parkinson’s Disease
Parkinsonism, Parkinson’s Disease Parkinsonism, Parkinson’s Disease
Parkinsonism, Parkinson’s Disease Dr. Siddharth Dutta
 
13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcohol 13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcohol Dr.Manish Kumar
 
Pharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons diseasePharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons diseaseQudsia Nuzhat
 
13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcohol13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcoholDr.Manish Kumar
 

Was ist angesagt? (20)

Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Parkinson by amir
Parkinson by amirParkinson by amir
Parkinson by amir
 
Parkinsons disease
Parkinsons diseaseParkinsons disease
Parkinsons disease
 
Antiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhritiAntiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhriti
 
Parkinson's disease pharmacology
Parkinson's disease pharmacologyParkinson's disease pharmacology
Parkinson's disease pharmacology
 
Anti-Parkinson Drugs
Anti-Parkinson DrugsAnti-Parkinson Drugs
Anti-Parkinson Drugs
 
Parkinson diseases
Parkinson diseasesParkinson diseases
Parkinson diseases
 
Anti parkinsonian drugs
Anti parkinsonian drugsAnti parkinsonian drugs
Anti parkinsonian drugs
 
Antiepileptic drugs : Dr Rahul Kunkulol's Power point preparations
Antiepileptic drugs : Dr Rahul Kunkulol's Power point preparationsAntiepileptic drugs : Dr Rahul Kunkulol's Power point preparations
Antiepileptic drugs : Dr Rahul Kunkulol's Power point preparations
 
Parkinsonism final
Parkinsonism final Parkinsonism final
Parkinsonism final
 
Drug induced parkinsonism
Drug induced parkinsonismDrug induced parkinsonism
Drug induced parkinsonism
 
Pathophysiology of Parkinsonism
Pathophysiology of ParkinsonismPathophysiology of Parkinsonism
Pathophysiology of Parkinsonism
 
Anti parkinsonian drugs
Anti parkinsonian drugsAnti parkinsonian drugs
Anti parkinsonian drugs
 
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
 
Parkinsonism, Parkinson’s Disease
Parkinsonism, Parkinson’s Disease Parkinsonism, Parkinson’s Disease
Parkinsonism, Parkinson’s Disease
 
Levodopa+carbidopa
Levodopa+carbidopaLevodopa+carbidopa
Levodopa+carbidopa
 
13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcohol 13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcohol
 
Pharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons diseasePharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons disease
 
13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcohol13.antiparkinsonian drugs, antiepileptics & alcohol
13.antiparkinsonian drugs, antiepileptics & alcohol
 

Andere mochten auch

Andere mochten auch (20)

Anti Parkinsonism
Anti ParkinsonismAnti Parkinsonism
Anti Parkinsonism
 
Pharmacology - Parkinsonism
Pharmacology - ParkinsonismPharmacology - Parkinsonism
Pharmacology - Parkinsonism
 
Anti parkinson
Anti parkinsonAnti parkinson
Anti parkinson
 
Antiparkinson's Drugs
Antiparkinson's DrugsAntiparkinson's Drugs
Antiparkinson's Drugs
 
Class antiparkinsonian drugs
Class antiparkinsonian drugsClass antiparkinsonian drugs
Class antiparkinsonian drugs
 
Antiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhriti Antiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhriti
 
Abnormal reactions of pupil
Abnormal reactions of pupilAbnormal reactions of pupil
Abnormal reactions of pupil
 
Pupil
PupilPupil
Pupil
 
GC-MS
GC-MSGC-MS
GC-MS
 
Hplc
Hplc Hplc
Hplc
 
Pericyclic reaction ii.pp
Pericyclic reaction ii.ppPericyclic reaction ii.pp
Pericyclic reaction ii.pp
 
pericyclic reaction
 pericyclic reaction pericyclic reaction
pericyclic reaction
 
Pericyclic Reaction
Pericyclic ReactionPericyclic Reaction
Pericyclic Reaction
 
Abnormal Pupil Reactions
Abnormal Pupil Reactions Abnormal Pupil Reactions
Abnormal Pupil Reactions
 
Microwave heating
Microwave heatingMicrowave heating
Microwave heating
 
Microwave synthesis
Microwave synthesisMicrowave synthesis
Microwave synthesis
 
Notes On Microwaves
Notes On MicrowavesNotes On Microwaves
Notes On Microwaves
 
Tandem Mass Spectroscopy Basics
Tandem Mass Spectroscopy BasicsTandem Mass Spectroscopy Basics
Tandem Mass Spectroscopy Basics
 
Microwave assisted organic synthesis
Microwave assisted organic synthesisMicrowave assisted organic synthesis
Microwave assisted organic synthesis
 
Tandem Mass spectrometry
Tandem Mass spectrometryTandem Mass spectrometry
Tandem Mass spectrometry
 

Ähnlich wie Antiparkinsons

Neurodegenerative disorders
Neurodegenerative disordersNeurodegenerative disorders
Neurodegenerative disordersMohammed Yousuf
 
Parkinson’s Disease.pptx
Parkinson’s Disease.pptxParkinson’s Disease.pptx
Parkinson’s Disease.pptxMebratGebreyesus
 
Parkinson's disease
Parkinson's diseaseParkinson's disease
Parkinson's diseaseSudharSan43
 
EXTRAPYRAMIDAL DISEASES NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES  NANNIKA PRADHANEXTRAPYRAMIDAL DISEASES  NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES NANNIKA PRADHANNannikaPradhan
 
EXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHANEXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHANthesalberry
 
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT Srinitha Busam
 
Parkinson's Disease
Parkinson's DiseaseParkinson's Disease
Parkinson's DiseaseSandra saju
 
antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...
antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...
antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...Vijay Salvekar
 
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Soujanya Pharm.D
 
Parkinson.pptx
Parkinson.pptxParkinson.pptx
Parkinson.pptxSaishDalvi
 
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh VaghelaNeurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghelajpv2212
 
Non motor manifestations of pd
Non motor manifestations of pdNon motor manifestations of pd
Non motor manifestations of pdNeurologyKota
 

Ähnlich wie Antiparkinsons (20)

Neurodegenerative disorders
Neurodegenerative disordersNeurodegenerative disorders
Neurodegenerative disorders
 
Parkinson s disease
Parkinson s diseaseParkinson s disease
Parkinson s disease
 
Parkinson’s Disease.pptx
Parkinson’s Disease.pptxParkinson’s Disease.pptx
Parkinson’s Disease.pptx
 
Prakash park
Prakash parkPrakash park
Prakash park
 
chapter 16
chapter 16chapter 16
chapter 16
 
Parkinson's disease
Parkinson's diseaseParkinson's disease
Parkinson's disease
 
EXTRAPYRAMIDAL DISEASES NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES  NANNIKA PRADHANEXTRAPYRAMIDAL DISEASES  NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES NANNIKA PRADHAN
 
EXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHANEXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHAN
EXTRAPYRAMIDAL DISEASES-DR NANNIKA PRADHAN
 
Case study of schizophrenia
Case study of schizophreniaCase study of schizophrenia
Case study of schizophrenia
 
ANTI MANIC DUGS
ANTI MANIC DUGSANTI MANIC DUGS
ANTI MANIC DUGS
 
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
 
Parkinson's Disease
Parkinson's DiseaseParkinson's Disease
Parkinson's Disease
 
antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...
antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...
antiparkinson drug-Dopamine precursors,levodopa,cabidopa,bromocriptyne,rponir...
 
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
 
Parkinson.pptx
Parkinson.pptxParkinson.pptx
Parkinson.pptx
 
Parkinson disease
Parkinson diseaseParkinson disease
Parkinson disease
 
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh VaghelaNeurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Non motor manifestations of pd
Non motor manifestations of pdNon motor manifestations of pd
Non motor manifestations of pd
 
Parkinson's Disease by Dr. Aryan
Parkinson's Disease by Dr. AryanParkinson's Disease by Dr. Aryan
Parkinson's Disease by Dr. Aryan
 

Mehr von MD Specialclass

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...MD Specialclass
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionMD Specialclass
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headachesMD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinomaMD Specialclass
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disordersMD Specialclass
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitisMD Specialclass
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosisMD Specialclass
 

Mehr von MD Specialclass (20)

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutrition
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headaches
 
Acute brain attack 911
Acute brain attack  911Acute brain attack  911
Acute brain attack 911
 
Hema intro anemia
Hema intro anemiaHema intro anemia
Hema intro anemia
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
Fever & id diet final
Fever & id diet finalFever & id diet final
Fever & id diet final
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disorders
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Thyroid
ThyroidThyroid
Thyroid
 
Dermatology dr.n.ramos
Dermatology   dr.n.ramosDermatology   dr.n.ramos
Dermatology dr.n.ramos
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitis
 
Pancreatic disease
Pancreatic diseasePancreatic disease
Pancreatic disease
 
Liver disease
Liver diseaseLiver disease
Liver disease
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosis
 

Kürzlich hochgeladen

Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxnegromaestrong
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...christianmathematics
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibitjbellavia9
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxAmita Gupta
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.MaryamAhmad92
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseAnaAcapella
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...ZurliaSoop
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptxMaritesTamaniVerdade
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Association for Project Management
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxAmanpreet Kaur
 

Kürzlich hochgeladen (20)

Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 

Antiparkinsons

Hinweis der Redaktion

  1. Many different areas within the brain are involved in a complex chain of decisions required for even the smallest muscular movement. For an action like walking, for example, the brain must first gather all the information it needs about your body position. For example, are you sitting, lying down, or already standing up? Where are your feet? Do you have your balance? Then, the brain must add in what it knows about where you will be going. For example, do your eyes tell your brain that you'll be crossing an open field of grass or a busy street? Do your feet detect that the ground is easy to walk on or that you could lose your balance because it is bumpy or slippery? Figure 1. Your brain and spinal cord - a message pathway that turns thought into motion. This information comes together in a central area of the brain, called the striatum, which controls many aspects of bodily motion. The striatum works with other areas of the brain, including a part called the substantia nigra, to send out the commands for balance and coordination. These commands go from the brain to the spinal cord through nerve networks to the muscles that will then help you to move (figure 1).
  2. he entire nervous system is made up of individual units called nerve cells. Nerve cells actually serve as a "communication network" within your body. To communicate with each other, nerve cells use a variety of chemical messengers called neurotransmitters. Neurotransmitters carry messages between nerve cells by crossing the space between cells, called the synapse (figure 2
  3. Neurotransmitters also allow the nervous system to communicate with the body's muscles and translate thought into motion. One especially important messenger is dopamine, which is manufactured in the substantia nigra. Dopamine is crucial to human movement and is the neurotransmitter that helps transmit messages to the striatum that both initiate and control your movement and balance. These dopamine messages make sure that muscles work smoothly, under precise control, and without unwanted movement. When a dopamine message is needed, a nerve cell that produces dopamine gathers packets within itself filled with dopamine particles. These packets carrying the dopamine move to the end of the nerve cell, open a "window," and release the dopamine particles into the synapse. The dopamine particles flow across the synapse and fit into special pockets on the outside of the neighboring, or receiving, nerve cell (figure 3). The receiving cell is now stimulated to send on the message, so it gathers its own packets of dopamine and passes along the message to the next nerve cell in the same way.
  4. After the receiving cell has been stimulated to pass along the message, the pockets then release the dopamine back into the synapse. To fine-tune coordination of movement, these "used" dopamine particles, along with any excess dopamine that did not originally fit into a pocket on the receiving cell, are broken down by a chemical in the synapse called MAO-B (figure 4). This is an important step in the precise control of muscle movement. Too much or too little dopamine can disrupt the normal balance between the dopamine system and another neurotransmitter system, and interfere with smooth, continuous movement.
  5. One way to illustrate how the muscle control process works is as follows: two buckets - one for the dopamine system and one for the acetylcholine system - balanced on either end of a seesaw (figure 5). This depicts the situation at rest when the dopamine and acetylcholine systems are balanced. When you decide to move, your brain understands the movement you want to make and it sends out a balance of dopamine and acetylcholine messages to keep that movement smooth.
  6. N= Substantia Nigra E= Globus Pallidus externa, S= Subthalamic nucleus, I/R= Globus Pallidus interna T = Thalamus Step1: Dopamine is normally produced in the pars compacta of the substantia nigra which has projections to the striatum. Step2: In the striatum, dopamine normally has an excitatory effect on D1 receptors. Step 3: This results in an increased production of GABA in neurones that project to the Gpi. GABA is an inhibitory neurotransmitter and reduces the output of the Gpi. In Parkinson’s however, Step One is removed and therefore Steps 2 and 3 don’t follow. The result is an increased output from the Gpi. (see step 8) Step4: Dopamine also has an inhibitory effect on the neurones in the striatum that make up the indirect pathway. Step 5: Inhibition here results in decreased production of GABA in the neurones that project to the Gpe. Step 6: Reduced inhibition of the Gpe results in an increased production of GABA by the neurones of the Gpe that project to the subthalamic nucleus. This results in an increased inhibitory effect on the subthalamic nucleus. Step 7: The Subthalamic nucleus, which projects to the Gpi, therefore reduces production of the excitatory neurotransmitter glutamate. In Parkinson’s disease however, the reverse occurs. There is no inhibition at step 4, therefore there is increased inhibition of the Gpe. This results in reduced production of GABA by the Gpe and reduced inhibition of the Subthalamic nucleus. It therefore produces more Glutamate and has an increased stimulatory effect on the Gpi. Step 8: In the normal situation, inhibition by the direct pathway and reduced stimulation by the indirect pathway would result in little production of GABA by the Gpi. This would mean that there would be little inhibition of the ventrolateral thalamus to which it projects via the lenticular fasciculus and the ansa lenticularis. However, in Parkinson’s disease, there is reduced inhibition by the direct pathway and increased stimulation by the indirect pathway. The result is an increased output of GABA and increased inhibition of the ventrolateral thalamus. Step 9: The ventrolateral nucleii of the thalamus are excitatory to the cortex. In the Parkinson’s patient therefore, the excessive inhibition of the thalamus from the Gpi could result in reduced excitation of the cortex and the classic symptoms of Parkinson’s disease, i.e. Bradykinesia, rigidity and tremor.
  7. THE GREATER DISTINCTION BWN ERGOT AND NON-ERGOT IS THEIR TOLERABILITY AND SPEED OF TITRATION
  8. methylphenyltetrahydropyridine
  9. methylphenyltetrahydopyridine